Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC for Chronic Neuropathic Pain
2022-502343-35-00Phase 2Authorised
- Sponsor
- Centre for Human Drug Research
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dronabinol in chronic neuropathic pain (2 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Pain severity NRS (weekly average) and Experience sampling method (ESM) NRS pain scores. Planned start Dec 2022; status: authorised.
02
Drugs
dronabinol
03
Conditions
chronic neuropathic pain
Beyond the preview
Go deeper on 2022-502343-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502343-35-00.